SURMOUNT-MAINTAIN: Tirzepatide for maintenance of body-weight reduction in adults with obesity
Estimated body-weight change from baseline to week 112 was -21.9% with continued maximum tolerated dose, -16.6% after reduction to 5 mg, and -9.9% after switching to placebo.
What this study tells us
This was an early human study designed mainly to measure exposure, tolerability or a preliminary signal. Without stronger blinded controls, it should not be treated as definitive proof of benefit.
Adults with obesity or overweight plus a weight-related comorbidity, without diabetes
n=441 enrolled; 378 randomized at week 60
Estimated body-weight change from baseline to week 112 was -21.9% with continued maximum tolerated dose, -16.6% after reduction to 5 mg, and -9.9% after switching to placebo.
All participants first received open-label tirzepatide; the randomized phase tests continuation or dose reduction versus withdrawal rather than initial efficacy in treatment-naive participants.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Estimated body-weight change from baseline to week 112 was -21.9% with continued maximum tolerated dose, -16.6% after reduction to 5 mg, and -9.9% after switching to placebo.